Close has invested £1.4m while London Technology Fund is also now a shareholder. Dexela develops 3D imaging technology, known as tomosynthesis, that’s used to detect breast cancer. The technology allows for earlier detection and reduces the need for patient callbacks. On its website, Dexela says the market for digital mammography is expected to exceed $1bn within the next few years and that tomosynthesis will dominate the market in the next five years. Dexela was founded in 2005 by Ed Bullard. It is headquartered in London but has a R&D facility in Sudbury, Massachusetts Commenting on the funding round, Bullard says: “Close Ventures has clearly demonstrated its thorough understanding of what we are trying to achieve and how to develop the business.” Picture source
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.